Neurocrine Biosciences (NBIX) : Perceptive Advisors scooped up 77,000 additional shares in Neurocrine Biosciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Nov 14, 2016. The investment management firm now holds a total of 2,797,967 shares of Neurocrine Biosciences which is valued at $153,244,653.Neurocrine Biosciences makes up approximately 9.93% of Perceptive Advisors’s portfolio.
Other Hedge Funds, Including , Two Sigma Advisers Lp added NBIX to its portfolio by purchasing 7,173 company shares during the most recent quarter which is valued at $392,865.Alliancebernstein reduced its stake in NBIX by selling 228,466 shares or 20.68% in the most recent quarter. The Hedge Fund company now holds 876,049 shares of NBIX which is valued at $46,421,837. Neurocrine Biosciences makes up approx 0.04% of Alliancebernstein’s portfolio.Blackrock Fund Advisors boosted its stake in NBIX in the latest quarter, The investment management firm added 64,921 additional shares and now holds a total of 2,009,633 shares of Neurocrine Biosciences which is valued at $88,685,104. Neurocrine Biosciences makes up approx 0.02% of Blackrock Fund Advisors’s portfolio.Rothschild Asset Management Inc boosted its stake in NBIX in the latest quarter, The investment management firm added 5 additional shares and now holds a total of 7,775 shares of Neurocrine Biosciences which is valued at $340,312. Neurocrine Biosciences makes up approx 0.01% of Rothschild Asset Management Inc’s portfolio.
Neurocrine Biosciences closed down -1.26 points or -2.41% at $51.01 with 6,48,876 shares getting traded on Monday. Post opening the session at $52.48, the shares hit an intraday low of $50.54 and an intraday high of $52.59 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Neurocrine Biosciences reported $-0.43 EPS for the quarter, beating the analyst consensus estimate by $ 0.14 according to the earnings call on Nov 2, 2016. Analyst had a consensus of $-0.57.During the same quarter in the previous year, the company posted $-0.40 EPS.
Many Wall Street Analysts have commented on Neurocrine Biosciences. Deutsche Bank Initiated Neurocrine Biosciences on Nov 3, 2016 to “Buy”, Price Target of the shares are set at $65.Needham Initiated Neurocrine Biosciences on Oct 18, 2016 to “Buy”, Price Target of the shares are set at $62.Leerink Partners Resumed Neurocrine Biosciences on Oct 4, 2016 to “Outperform”, Price Target of the shares are set at $70.
Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.